198 related articles for article (PubMed ID: 35249925)
1. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
Shindo A; Yamasaki M; Uchino K; Yamasaki M
Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
[TBL] [Abstract][Full Text] [Related]
4. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
5. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
6. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
[TBL] [Abstract][Full Text] [Related]
8. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
10. Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy.
Nishimura T; Ninomiya K; Nakashima M; Akagi S; Kuribayashi T; Higo H; Hotta K; Maeda Y; Ito H; Kiura K
Intern Med; 2023 May; 62(9):1319-1322. PubMed ID: 36130891
[TBL] [Abstract][Full Text] [Related]
11. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
[TBL] [Abstract][Full Text] [Related]
12. Fatal myocarditis after the first dose of nivolumab.
Zomborska E; Kasperova S; Slopovsky J; Pazderová N; Kasperova B; Penz P; Nyitrayová O; Salek T; Porsok S; Mladosievicova B; Mego M
Klin Onkol; 2022; 35(6):486-492. PubMed ID: 36513516
[TBL] [Abstract][Full Text] [Related]
13. Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature.
Wang F; Liu Y; Xu W; Zhang C; Lv J; Ma S
J Med Case Rep; 2021 Jul; 15(1):336. PubMed ID: 34225811
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms.
Champion SN; Stone JR
Mod Pathol; 2020 Jan; 33(1):99-108. PubMed ID: 31534205
[TBL] [Abstract][Full Text] [Related]
15. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
17. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
18. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.
Ji C; Roy MD; Golas J; Vitsky A; Ram S; Kumpf SW; Martin M; Barletta F; Meier WA; Hooper AT; Sapra P; Khan NK; Finkelstein M; Guffroy M; Buetow BS
Clin Cancer Res; 2019 Aug; 25(15):4735-4748. PubMed ID: 31085720
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
20. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
